---
title: "Sector Update: Health Care Stocks Advance Late Afternoon"
description: "Health care stocks saw gains late Monday, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF rising 0.5%. Biogen's shares increased 1% following FDA review news fo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273747613.md"
published_at: "2026-01-26T20:58:00.000Z"
---

# Sector Update: Health Care Stocks Advance Late Afternoon

> Health care stocks saw gains late Monday, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF rising 0.5%. Biogen's shares increased 1% following FDA review news for Leqembi. Sarepta Therapeutics surged 7.2% on positive trial results for Elevidys, while Cogent Biosciences rose 3.2% after receiving breakthrough therapy designation. Conversely, Merck's shares fell 0.7% after dropping its bid for Revolution Medicines, which plummeted nearly 17%.

03:58 PM EST, 01/26/2026 (MT Newswires) -- Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each increasing 0.5%.

The iShares Biotechnology ETF (IBB) added 0.4%.

In corporate news, Biogen (BIIB) shares rose 1%. The company and Eisai said Sunday that the US Food and Drug Administration has agreed to review their supplemental marketing application for a weekly subcutaneous autoinjector version of Leqembi for Alzheimer's disease.

Sarepta Therapeutics ( SRPT ) shares jumped 7.2% after it said that three-year results from part 1 of a phase 3 trial of its gene therapy Elevidys in ambulatory patients with Duchenne muscular dystrophy showed continued benefit.

Cogent Biosciences ( COGT ) shares rose 3.2% after it said Monday the US Food and Drug Administration has granted breakthrough therapy designation for bezuclastinib in combination with sunitinib for people with gastrointestinal stromal tumors, or GIST.

Merck ( MRK ) has dropped its bid to acquire Revolutions Medicines (RVMD) over a disagreement on price, The Wall Street Journal reported over the weekend. Media outlets reported earlier in January that Merck ( MRK ) was in advanced talks on a potential deal that could have valued the oncology company at around $30 billion. Merck ( MRK ) shares shed 0.7%, and Revolution tumbled nearly 17%.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [COGT.US - Cogent Biosciences](https://longbridge.com/en/quote/COGT.US.md)
- [IBRN.US - iShares Neuroscience And Healthcare ETF](https://longbridge.com/en/quote/IBRN.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [SRPU.US - Tradr 2X Long SRPT Daily ETF](https://longbridge.com/en/quote/SRPU.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [IHI.US - iShares US Medical Devices](https://longbridge.com/en/quote/IHI.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [XHS.US - SPDR S&P Health](https://longbridge.com/en/quote/XHS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Biocon aims for revenue surge with rollout of generic weight-loss drugs | Biocon aims for high double-digit revenue growth with the global launch of generic weight-loss drugs, including versions | [Link](https://longbridge.com/en/news/276028392.md) |
| Jefferies Reaffirms Their Hold Rating on Novartis AG (NOVN) | Jefferies analyst James Vane has reaffirmed a Hold rating on Novartis AG (NOVN) with a price target of CHF110.00. Vane,  | [Link](https://longbridge.com/en/news/276102881.md) |
| Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus | Biogen (NASDAQ:BIIB) presented its immunology and neurology development priorities at the Piper Sandler symposium, focus | [Link](https://longbridge.com/en/news/275926142.md) |
| AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch | AbbVie (ABBV) is conducting a Phase 2 clinical trial for AGN-151607-DP, a botulinum toxin-based therapy aimed at improvi | [Link](https://longbridge.com/en/news/275926867.md) |
| Biogen Elects Maria C. Freire as New Board Chair | Biogen Inc. has announced that Dr. Maria C. Freire will become Chair of the Board of Directors after the 2026 Annual Mee | [Link](https://longbridge.com/en/news/275665195.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.